Single Drug Adverse Effect Pathway Anchored Network Pharmacology Planner

Problem

Single-drug adverse-effect network pharmacology projects often string together target lists, pathway enrichment, and molecular docking without a clear evidence boundary. A hub gene does not prove biological centrality, and docking does not prove mechanism. This skill addresses that gap for one fixed drug and one fixed adverse-effect endpoint, producing an executable research design rather than a generic literature summary.

How It Works

The planner follows a pathway-anchored logic: fix the drug and endpoint → build the target overlap → anchor biologically interpretable pathways → nominate core targets → use docking only as plausibility support. It infers study type, resource constraints, and goal emphasis, then compares Lite, Standard, Advanced, and Publication+ workload options. The output includes goals, required data, major modules, workload, figure complexity, evidence ceiling, and dependency maps. A reference layer supports design decisions with verified PubMed-indexed records, DOIs, PMIDs, or stable links; unverified sources are explicitly marked as unavailable.

Boundaries

Use this for single-drug, single-adverse-effect mechanism papers, such as drug-induced liver injury, nephrotoxicity, or QT prolongation. It does not provide patient-specific medication advice, dosing, prescribing guidance, or clinical decision support. It also avoids causal toxicity claims when only network-pharmacology evidence is present. Multi-drug exposure comparisons, pure pharmacovigilance studies, and wet-lab-only toxicology projects are outside its scope.